Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) have earned an average rating of “Hold” from the twenty-three analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $249.37.

ILMN has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and set a $290.00 price target on shares of Illumina in a research report on Wednesday, February 8th. Argus lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, January 25th. They noted that the move was a valuation call. Barclays decreased their target price on Illumina from $160.00 to $150.00 and set an “underweight” rating on the stock in a report on Wednesday, February 8th. OTR Global upgraded Illumina from a “mixed” rating to a “positive” rating in a research report on Tuesday, December 20th. Finally, Scotiabank started coverage on Illumina in a report on Wednesday, January 4th. They issued a “sector perform” rating and a $216.00 target price on the stock.

Illumina Stock Down 1.4 %

Shares of NASDAQ ILMN opened at $224.95 on Friday. The stock has a fifty day moving average price of $208.40 and a 200 day moving average price of $208.60. The company has a market cap of $35.54 billion, a P/E ratio of -8.03, a P/E/G ratio of 8.27 and a beta of 1.15. The company has a current ratio of 1.28, a quick ratio of 1.08 and a debt-to-equity ratio of 0.23. Illumina has a 12-month low of $173.45 and a 12-month high of $371.16.

Illumina (NASDAQ:ILMN – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.11). The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The business’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Research analysts anticipate that Illumina will post 1.41 EPS for the current fiscal year.

Insider Activity

In other Illumina news, SVP Aimee L. Hoyt sold 3,917 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the completion of the sale, the senior vice president now directly owns 2,881 shares in the company, valued at $573,491.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Illumina news, SVP Alexander Aravanis sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total transaction of $1,088,992.52. Following the transaction, the senior vice president now owns 2,922 shares of the company’s stock, valued at approximately $589,484.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Aimee L. Hoyt sold 3,917 shares of Illumina stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the transaction, the senior vice president now owns 2,881 shares of the company’s stock, valued at approximately $573,491.86. The disclosure for this sale can be found here. Insiders have sold a total of 11,186 shares of company stock valued at $2,255,837 in the last 90 days. 0.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On Illumina

A number of large investors have recently made changes to their positions in the company. Twin Tree Management LP bought a new position in Illumina in the 3rd quarter valued at about $1,147,000. M&G Investment Management Ltd. raised its position in Illumina by 12.3% during the second quarter. M&G Investment Management Ltd. now owns 105,825 shares of the life sciences company’s stock valued at $19,472,000 after purchasing an additional 11,555 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Illumina by 31.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 5,437 shares of the life sciences company’s stock valued at $1,002,000 after purchasing an additional 1,302 shares in the last quarter. Alaethes Wealth LLC increased its stake in shares of Illumina by 19.5% in the 2nd quarter. Alaethes Wealth LLC now owns 3,791 shares of the life sciences company’s stock valued at $699,000 after purchasing an additional 619 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of Illumina by 1.1% in the third quarter. Amalgamated Bank now owns 39,880 shares of the life sciences company’s stock worth $7,609,000 after acquiring an additional 452 shares during the last quarter. Institutional investors own 87.97% of the company’s stock.

About Illumina

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.